Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,405 across all filing types
Latest filing 2026-04-01 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
6-K - ASTRAZENECA PLC (0000901832) (Filer)
Regulatory Filings
2026-04-01 English
Total Voting Rights and Admission of Shares
Share Issue/Capital Change Classification · 85% confidence The document is an RNS announcement by AstraZeneca that (1) confirms its total voting rights under FCA DTR 5.6.1 and (2) notifies the admission of 491 further ordinary shares to trading under the company’s existing block admission (employee share schemes). This is not a financial report or AGM material but a disclosure of new share issuance/admission to the market, fitting the definition of a share issue/capital change announcement.
2026-04-01 English
Total Voting Rights and Admission of Shares
Share Issue/Capital Change Classification · 88% confidence The document is an RNS announcement by AstraZeneca disclosing the total number of voting rights and the admission of further ordinary shares to trading under existing block admission (i.e., a share issuance/capital change). This fits the definition of a Share Issue/Capital Change notification rather than a quarterly or full report, AGM materials, or vote results. Accordingly, it is classified under code SHA.
2026-04-01 English
6-K - ASTRAZENECA PLC (0000901832) (Filer)
Regulatory Filings
2026-03-31 English
Efzimfotase alfa Ph3 program show positive results
Regulatory Filings Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement from AstraZeneca containing clinical trial results and inside information. It is not a formal financial report (Annual Report, Interim Report, Earnings Release), nor is it a proxy statement, dividend notice, or management change announcement. It provides detailed clinical update content under an RNS number, making it a general regulatory filing. Therefore, the correct classification is RNS.
2026-03-31 English
Efzimfotase alfa Ph3 program show positive results
Regulatory Filings Classification · 95% confidence The document is an RNS regulatory announcement (“RNS Number: 7141Y”) by AstraZeneca disclosing positive Phase III clinical trial results for efzimfotase alfa. It is not a formal financial report (no financial statements or earnings metrics), nor a management presentation, dividend notice, M&A, or other specific category. It falls into the general regulatory announcements category for miscellaneous corporate updates delivered via the RNS service.
2026-03-31 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.